CD44+ NPC cells were previously shown to exhibit higher proliferative ability and higher expression of the stemness antigens OCT4 and BMI1 [20]; they were also resistant to chemotherapy and radiotherapy. This evidence concerns the gene BMI1 and nasopharyngeal carcinoma.